Lunai Bioworks Inc LNAI
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-11-18 |
| Shares Out. | 4,530,000 |
| Website | renovarobio.com/ ↗ |
| Phone | 18885282677 |
| Employees | 29 |
| Revenue | $20,942 |
| Gross Profit | $20,942 |
| Net Income | -$2.6M |
| Free Cash Flow | -$5.3M |
| Total Assets | $9.9M |
| Total Liabilities | $19.4M |
| Equity | -$9.6M |
About Lunai Bioworks Inc
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
Lunai Bioworks Inc is a publicly traded company under the ticker symbol LNAI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.